Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
With
GlaxoSmithKline
The purpose of this study is to assess the safety and feasibility of concurrent treatment of nicotine dependence (cigarette smoking) and acute depression. Participants who meet DSM-IV criteria for both nicotine dependence and acute major depression will be given pharmacological treatment for both disorders at the same time, along with a brief behavioral intervention for smoking cessation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age at least 18 at the beginning of the study
Smoking at least 10 cigarettes a day (1/2 pack)
Meets DSM-IV criteria for major depressive episode
You may not be if
Currently pregnant
Currently breastfeeding
Currently diagnosed with a seizure disorder, liver disease, kidney disease, congestive heart failure or diabetes mellitis
History of a seizure, seizure disorder, significant head trauma or central nervous system tumor
Family history of seizures
Currently using intravenous drugs
Currently using any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.) on a daily basis
Currently using any over-the-counter stimulants and anorectics (diet pills)
Currently on fluoxetine (Prozac), bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL) or any other antidepressants, monoamine oxidase inhibitors, antipsychotics, benzodiazepines, theophylline, systemic steroids or levodopa
Currently on NRT or bupropion (Zyban)
Current or past diagnosis of anorexia nervosa
Previous allergic response to fluoxetine, bupropion, or NRT
Previous failed quit attempt using NRT and bupropion in combination
Current suicidal ideation
Current or past psychosis, mania/hypomania, or any other Axis I or Axis II psychiatric diagnosis other than major depression and nicotine dependence
